JP2014532865A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532865A5
JP2014532865A5 JP2014538961A JP2014538961A JP2014532865A5 JP 2014532865 A5 JP2014532865 A5 JP 2014532865A5 JP 2014538961 A JP2014538961 A JP 2014538961A JP 2014538961 A JP2014538961 A JP 2014538961A JP 2014532865 A5 JP2014532865 A5 JP 2014532865A5
Authority
JP
Japan
Prior art keywords
tsg
hyaluronan
sample
multimer
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014538961A
Other languages
English (en)
Japanese (ja)
Other versions
JP6162707B2 (ja
JP2014532865A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/061743 external-priority patent/WO2013063155A2/en
Publication of JP2014532865A publication Critical patent/JP2014532865A/ja
Publication of JP2014532865A5 publication Critical patent/JP2014532865A5/ja
Application granted granted Critical
Publication of JP6162707B2 publication Critical patent/JP6162707B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014538961A 2011-10-24 2012-10-24 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法 Expired - Fee Related JP6162707B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161628187P 2011-10-24 2011-10-24
US61/628,187 2011-10-24
US201161559011P 2011-11-11 2011-11-11
US61/559,011 2011-11-11
US201161630765P 2011-12-16 2011-12-16
US61/630,765 2011-12-16
US201261714700P 2012-10-16 2012-10-16
US61/714,700 2012-10-16
PCT/US2012/061743 WO2013063155A2 (en) 2011-10-24 2012-10-24 Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2014532865A JP2014532865A (ja) 2014-12-08
JP2014532865A5 true JP2014532865A5 (https=) 2015-09-03
JP6162707B2 JP6162707B2 (ja) 2017-07-12

Family

ID=47116517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014538961A Expired - Fee Related JP6162707B2 (ja) 2011-10-24 2012-10-24 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法

Country Status (14)

Country Link
US (2) US8846034B2 (https=)
EP (2) EP2771028A2 (https=)
JP (1) JP6162707B2 (https=)
KR (1) KR101828828B1 (https=)
CN (1) CN104093415B (https=)
AU (1) AU2012328880B2 (https=)
BR (1) BR112014009797A2 (https=)
CA (1) CA2853358A1 (https=)
EA (1) EA030440B1 (https=)
HK (1) HK1213206A1 (https=)
IL (1) IL232229B (https=)
MX (1) MX342735B (https=)
SG (1) SG11201401797TA (https=)
WO (1) WO2013063155A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
KR20130116386A (ko) 2008-04-14 2013-10-23 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
EA022752B1 (ru) * 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
WO2012012300A2 (en) 2010-07-20 2012-01-26 Halozyme, Inc. Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
JP6162707B2 (ja) * 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
CN108686203A (zh) 2012-04-04 2018-10-23 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
WO2014062856A1 (en) * 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
TW201427989A (zh) * 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
EP3160990A2 (en) * 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
US20170327553A1 (en) * 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
AU2015278744B2 (en) * 2014-06-25 2018-09-27 Alcon Inc. Compositions and methods for visualization of the vitreous
AU2015287696B2 (en) 2014-07-10 2018-06-14 Academia Sinica Multi-drug delivery system and uses thereof
PT3186281T (pt) 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
KR101695792B1 (ko) * 2014-09-04 2017-01-12 디오셀 주식회사 신규 세포막 투과 펩티드 및 생리활성 물질 전달체로서의 그의 용도
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7118886B2 (ja) 2015-06-03 2022-08-16 エアラン セル テクノロジーズ, インコーポレイテッド 幹細胞からの有益因子の産生および送達のための方法およびデバイス
PE20181363A1 (es) 2015-09-23 2018-08-27 Genentech Inc Variantes optimizadas de anticuerpos anti-vegf
US10578702B2 (en) 2015-10-02 2020-03-03 Uab Research Foundation Imaging phantom and systems and methods of using same
KR101698003B1 (ko) * 2016-06-20 2017-01-19 여오영 퀴닌 염 현탁액을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
EP3516397A1 (en) 2016-09-23 2019-07-31 Ventana Medical Systems, Inc. Methods and systems for scoring extracellular matrix biomarkers in tumor samples
WO2018102762A1 (en) 2016-12-02 2018-06-07 Avelas Biosciences, Inc. Nerve labeling compositions and uses thereof
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
PL3593139T3 (pl) * 2017-03-07 2025-11-17 Elypta Ab Biomarkery nowotworowe
CN110004105B (zh) * 2018-01-05 2023-09-29 上海普佑生物医药有限公司 一种蛋白在细胞培养中的应用
US20200246489A1 (en) * 2019-02-01 2020-08-06 Glympse Bio, Inc. Detecting architectural remodelling in cells, extracellular matrix, and the tissue microenvironment
US20220202899A1 (en) * 2019-04-30 2022-06-30 Haplnscience inc. Composition for prevention or treatment of hair loss including hapln1
CN119570901A (zh) * 2019-05-07 2025-03-07 建新公司 前药组合物中药物浓度的量化方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR102166453B1 (ko) * 2020-02-03 2020-10-15 중앙대학교 산학협력단 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물
CN111218452B (zh) * 2020-02-25 2022-11-15 芜湖天明生物技术有限公司 一种重组人tsg-6基因、重组人tsg-6蛋白标准品及其制备方法和应用
WO2021203051A1 (en) * 2020-04-03 2021-10-07 Standard Of Care Corporation Aerosolized hyaluronidase and/or 4-methylumbelliferone compositions and methods of using same to treat respiratory diseases or disorders
CN111449684B (zh) * 2020-04-09 2023-05-05 济南康硕生物技术有限公司 心脏超声标准扫查切面快速获取方法及系统
US11883245B2 (en) 2021-03-22 2024-01-30 Verb Surgical Inc. Deep-learning-based real-time remaining surgery duration (RSD) estimation
AU2023217074A1 (en) * 2022-02-10 2024-08-15 Kodiak Sciences Inc. Methods of purifying a product
CN117074683A (zh) * 2022-05-09 2023-11-17 四川大学 检测c1qbp蛋白表达水平的试剂在制备口腔癌筛查或预后试剂盒中的用途
CN117664885B (zh) * 2023-11-28 2024-05-07 中国计量科学研究院 一种织物中透明质酸含量的定量检测方法
CN118766789A (zh) * 2024-06-14 2024-10-15 江苏雪豹日化有限公司 一种除螨剂、其制备方法及应用
CN120400103B (zh) * 2025-04-25 2026-02-03 上海齐鲁制药研究中心有限公司 新型ph20突变体酶
CN121186363B (zh) * 2025-11-25 2026-04-10 长兴固容生物科技有限公司 一种用于泛癌筛查、诊断的标志物组及其用途

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2488564A (en) 1947-06-03 1949-11-22 Orthe Pharmaecutlcal Corp Preparation of hyaluronidase
US2488565A (en) 1947-06-04 1949-11-22 Ortho Pharma Corp Preparation of hyaluronidase
US2676139A (en) 1950-09-01 1954-04-20 American Home Prod Hyaluronidase
US2808362A (en) 1952-05-02 1957-10-01 Armour & Co Preparation of hyaluronidase
US2795529A (en) 1954-06-17 1957-06-11 American Home Prod Stabilized hyaluronidase solution containing calcium chloride
US2806815A (en) 1955-04-12 1957-09-17 Ortho Pharma Corp Stabilized hyaluronidase
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
CA1319593C (en) 1987-03-03 1993-06-29 Kenji Chichibu Method of assaying high molecular hyaluronic acid and kit of reagents for such assay
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DK0400472T3 (da) 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
EP0576592B1 (en) 1991-03-18 2000-05-31 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5872094A (en) 1993-01-06 1999-02-16 The General Hospital Corporation Method for attaching cartilaginous tissue, cartilage matrix protein or link protein to a surface
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
GEP20002180B (en) 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5747027A (en) 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6193963B1 (en) 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
US6103525A (en) 1996-10-17 2000-08-15 The Regents Of The University Of California Hybridoma cell lines producing monoclonal antibodies that bind to human plasma hyaluronidase
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
CA2237051A1 (en) 1997-12-19 1999-06-19 Eva A. Turley Enhanced affinity hyaluronan binding peptides
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル,コーポレイション 近位の反応性基を持つポリ(エチレングリコール)誘導体
EP1064011A1 (en) 1998-03-13 2001-01-03 EntreMed, Inc. Metastatin and hyaluronate binding proteins and methods of use
CN1314992A (zh) 1998-07-03 2001-09-26 奈勒斯菲尔德控制有限公司 流体测量的方法和装置
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6872546B1 (en) 1998-12-23 2005-03-29 Human Genome Sciences, Inc. Hyaluronan-binding proteins and encoding genes
US6852696B2 (en) 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
EP1196623B8 (en) 1999-07-23 2008-05-21 Forensic Science Service Ltd Method for detecting single nucleotide polymorphisms
US6461802B1 (en) 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
EP1345628B1 (en) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
EP1578368A4 (en) 2002-11-12 2008-01-23 Genentech Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
GB0229734D0 (en) 2002-12-23 2003-01-29 Qinetiq Ltd Grading oestrogen and progesterone receptors expression
US8026209B2 (en) 2003-02-10 2011-09-27 Bbb Holding B.V. Methods and compositions for targeting agents into and across the blood-barrier and other endothelial cell microvascular barriers
BRPI0407882B1 (pt) 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
US7257268B2 (en) 2003-02-28 2007-08-14 Aperio Technologies, Inc. Systems and methods for image pattern recognition
US20090123367A1 (en) 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
EP2644206B1 (en) 2003-05-23 2019-04-03 Nektar Therapeutics PEG derivatives containing two PEG chains
CA2541438C (en) 2003-10-10 2013-11-26 Meditech Research Limited The modulation of hyaluronan synthesis and degradation in the treatment of disease
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
WO2005118799A1 (en) 2004-04-15 2005-12-15 Ista Pharmaceuticals, Inc. Ovine hyaluronidase
GB0408351D0 (en) 2004-04-15 2004-05-19 Plasso Technology Ltd Reversible binding surface
US7112687B2 (en) 2004-07-15 2006-09-26 Indena, S.P.A. Methods for obtaining paclitaxel from taxus plants
US7723472B2 (en) 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
CA2610791C (en) 2005-06-08 2015-12-01 Cangene Corporation Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
WO2007133725A1 (en) 2006-05-12 2007-11-22 University Of Miami Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma
US8023714B2 (en) 2007-06-06 2011-09-20 Aperio Technologies, Inc. System and method for assessing image interpretability in anatomic pathology
SI4269578T1 (sl) 2008-03-06 2024-07-31 Halozyme, Inc. Sestava topne hialuronidaze
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
KR20130116386A (ko) * 2008-04-14 2013-10-23 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
US8034630B2 (en) 2008-04-15 2011-10-11 Wako Pure Chemical Industries, Ltd. Protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
JP5551702B2 (ja) 2008-09-16 2014-07-16 ヒストロックス,インコーポレイテッド. バイオマーカー発現の再現性のある定量
EA022752B1 (ru) 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
WO2010124296A2 (en) 2009-04-24 2010-10-28 Tissuetech, Inc. Compositions containing hc•ha complex and methods of use thereof
HUE028832T2 (en) 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
US20110111435A1 (en) 2009-11-06 2011-05-12 SlidePath Limited Detecting Cell Surface Markers
CN101899118B (zh) 2010-04-22 2012-05-30 曹利民 一种融合蛋白HABP-mKate及其制备方法和应用
WO2012012300A2 (en) 2010-07-20 2012-01-26 Halozyme, Inc. Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
CA2839512C (en) 2011-06-17 2018-01-02 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
JP6162707B2 (ja) * 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
CN108686203A (zh) 2012-04-04 2018-10-23 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ph20玻尿酸酶變異體及其用途

Similar Documents

Publication Publication Date Title
JP2014532865A5 (https=)
TWI818938B (zh) Gpcr異聚體抑制劑及其用途
EP2699256B1 (en) Compositions and methods for the treatment of neuromyelitis optica
EP3583118B1 (en) Transferrin receptor transgenic models
US11612150B2 (en) Transferrin receptor transgenic models
ES2924394T3 (es) Moléculas de unión a CXCR4
JP2020524139A (ja) 骨髄増殖性腫瘍関連骨髄線維症及び貧血を治療するための方法
JP2016536330A5 (https=)
RS64002B1 (sr) Anti-kancerski fuzioni polipeptid
JP6345690B2 (ja) 改変axlペプチド及び抗転移療法のaxlシグナル伝達阻害におけるその使用
CN111732652A (zh) 免疫系统调节器
JP2018535964A (ja) 線維芽細胞増殖因子(fgf)1アナログによるステロイド誘導性高血糖の処置
US20090214517A1 (en) Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
JP2023552919A (ja) Wnt受容体rykに対する抗体バリアント
JP2003530109A (ja) エルビンをコードする遺伝子及びその診断及び治療的使用
JP5093578B2 (ja) 受容体型プロテインチロシンホスファターゼPtprzによるErbB4シグナルの抑制
TW202511284A (zh) 包含robo結構域的蛋白及其醫藥用途
KR20240139004A (ko) 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체
EP4584286A1 (en) Targeted pd-l1 degradation
EP4479075A1 (en) Propeptide of lysyl oxidase for treatment of cancer
Garlick Interactions Between the Actin Cytoskeleton and Anthrax Toxin Receptor 1 (ANTXR1)
Wang The nature and consequences of molecular interactions of the metastasis-inducing protein, S100A4
HK1195000B (en) Compositions and methods for the treatment of neuromyelitis optica
HK1195000A (en) Compositions and methods for the treatment of neuromyelitis optica
BR112017020445B1 (pt) Proteína de fusão, molécula de ácido nucleico, célula hospedeira, método de produção de uma proteína de fusão, uso de uma ou mais proteínas de fusão e composição farmacêutica